Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2333 • ACR Convergence 2025
Validation of a Corrected Axial Spondyoarthritis Metrology Index in 9 Randomized Clinical Trials
Dafne capelusnik¹, Philip Gardiner², Annelies Boonen³, Elena Nikiphorou⁴ and Sofia Ramiro⁵, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Altnagelvin Hospital, Londonderry, United Kingdom, ³Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, ⁴King’s College London, London, United Kingdom, ⁵Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The MOBILITY study showed that BASMI often misclassifies spinal mobility, especially in older and taller individuals. To address this, the Corrected AxSpA Metrology Index…
Abstract Number: 1465 • ACR Convergence 2025
Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compan¹, Philip J. Mease², Lianne S. Gensler³, Martin Rudwaleit⁴, Yael Klionsky⁵, Jayne Stigler⁶, Erin Mancl⁷, Shirley Chen⁸, Jamie Urbanik⁹ and Xenofon Baraliakos¹⁰, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, ⁵Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ⁶AbbVie, Round Lake, IL, ⁷AbbVie, Chicago, IL, ⁸AbbVie, Somerset, NJ, ⁹AbbVie, Grayslake, IL, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Treatment with the oral JAK inhibitor upadacitinib (UPA) has shown efficacy and safety in patients with active axial spondyloarthritis (axSpA), including both radiographic (r-axSpA,…
Abstract Number: 1418 • ACR Convergence 2025
Impact of Type 2 Diabetes Mellitus on Cardiovascular Outcomes in Patients with Ankylosing Spondylitis on NSAID Therapy
Godbless Ajenaghughrure¹, Sila Mateo Faxas², Gurjot Singh³, Nirys Mateo Faxas⁴, Kim Nguyen³, Nicole Tejeda⁵ and Kimberly Ramirez Bonetti⁶, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Good Samaritan Hospital, Cincinnati, OH, ³Trihealth Good Samaritan Hospital, Cincinnati, ⁴Independent Author, Santo Domingo, Dominican Republic, ⁵Independent Author, Cincinnati, ⁶Independent Author, cincinnati, OH
Background/Purpose: Patients with ankylosing spondylitis (AS) have increased cardiovascular risk, potentially exacerbated by NSAID therapy. However, the additional impact of Type 2 diabetes mellitus (T2DM)…
Abstract Number: 0817 • ACR Convergence 2025
More than 40% of Older Adults with Rheumatic Diseases Are Prescribed Opioid Medications
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: Patients with rheumatic diseases commonly experience acute or chronic pain that may lead to both short- and long-term opioid use. Many patients do not…
Abstract Number: 2638 • ACR Convergence 2025
ASembleNet: A Hybrid AI Model for MRI-Based Classification of Ankylosing Spondylitis
Miral Gharib¹, Amith Khandakar², Mohamed Arselene Ayari³ and Samar Al emadi⁴, ¹hamad medical corporation, Doha, Qatar, ²Department of Electrical Engineering, College of Engineering, Qatar University, Doha, Qatar, Doha, Qatar, ³Department of Civil and Environmental Engineering, College of Engineering, Qatar University, Doha, Qatar, ⁴Hamad medical corporation, Doha, Qatar
Background/Purpose: Ankylosing spondylitis (AS) is a progressive inflammatory disease with delayed diagnosis due to subtle early imaging findings. We present ASembleNet, a deep learning model…
Abstract Number: 2331 • ACR Convergence 2025
Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time
Marc van Essen¹, Dafne capelusnik², Désirée Van Der Heijde³, Robert Landewé⁴, Wim van Lankveld⁵, Astrid Van Tubergen⁶, Sofia Ramiro⁷ and Annelies Boonen⁸, ¹Maastricht University, Zeist, Netherlands, ²Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁵HAN University of Applied Sciences, Arnhem, Netherlands, ⁶Maastricht university, Maastricht, Netherlands, ⁷Leiden University Medical Center, Bunde, Netherlands, ⁸Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands
Background/Purpose: To identify patient characteristics and disease phenotypes associated with coping strategies in axial spondyloarthritis (axSpA), and assess whether coping strategies change over time.Methods: Data…
Abstract Number: 1454 • ACR Convergence 2025
Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Philip J. Mease¹, Denis Poddubnyy², Rajan Bajracharya³, Barbara Ink³, Myriam Manente⁴, Luke Peterson⁵, Katy White⁶, Peter Nash⁷ and Lianne S. Gensler⁸, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³UCB, Slough, England, United Kingdom, ⁴UCB, Braine-L'Alleud, Belgium, ⁵UCB, Morrisville, NC, ⁶UCB, Slough, United Kingdom, ⁷School of Medicine, Griffith University, Brisbane, Australia, ⁸Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Previous analyses of phase (Ph)2b/3 safety data (data…
Abstract Number: 1410 • ACR Convergence 2025
Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
Connor Vershel¹, Mark Hwang², John Reveille³, Seokhun Kim⁴, Matthew A. Brown⁵, Michael Weisman⁶, Mariko Ishimori⁶ and Michael Ward⁷, ¹Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine at the University of Texas Health Science Center at Houston, Houston, TX, ²UTHealth Houston, Houston, TX, ³Department of Medicine, University of Texas Medical Center, Houston, TX, ⁴UTHealth Houston, Houston, ⁵Genomics England, London, United Kingdom, ⁶Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD
Background/Purpose: In axial spondyloarthritis cohorts, patient reported outcomes are vital for tracking disease progression and response to therapy. However, many cohorts enrolled prior to the…
Abstract Number: 0547 • ACR Convergence 2025
Determinants of Difficult-to-Manage Axial Spondyloarthritis: Results from a Prospective Cohort Study
Patricia Remalante-Rayco¹, Laura Passalent², Manal Alnasser³, Tina Chim¹, Robert Inman¹, Nigil Haroon⁴ and Denis Poddubnyy⁵, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³King Abdulaziz Medical City, Riyadh, Saudi Arabia, ⁴Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) group has recently introduced a consensus-based definition for difficult-to-manage (D2M) axial spondyloarthritis (axSpA) to identify patients with…
Abstract Number: 2636 • ACR Convergence 2025
Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
Raj Sengupta¹, Anthony Marotta², Walter P. Maksymowych³, Charlotte Cavill⁴, Stephen Bleakley² and Norma Biln⁵, ¹Royal National Hospital for Rheumatic Diseases, Bath, England, United Kingdom, ²Augurex Life Sciences Corp, Vancouver, BC, Canada, ³Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ⁴Royal United Hospitals Bath NHS Foundation Trust, Bath, England, United Kingdom, ⁵Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: People with axial spondyloarthritis (axSpA), typically present with persistent back pain and experience up to a 10-year diagnostic delay that may lead to irreversible…
Abstract Number: 2326 • ACR Convergence 2025
Impact of Regular Exercise, Mobility Impairment, and Obesity on Quality of Life in Patients with Axial Spondyloarthritis: A Cross-Sectional Analysis from the Brazilian Registry of Spondyloarthritis
Rafael Bassara Macedo¹, Maria Eduarda Veiga², Gustavo Resende³, Marcelo Pinheiro⁴, Claudia Marques⁵, Adriana Marinho⁶, Andressa Soares⁷, Cleandro Pires⁸, Débora Rodrigues⁹, Eduarda Souza¹⁰, Glaucio Castro¹¹, Guilherme Bulbol¹², Jamile Carneiro¹³, José Mauro Fernandes¹⁴, Manuella Ochtrop¹⁵, Maria Bernadete Gavi¹⁶, Michel Yazbek¹⁷, Nara Cavalcanti¹⁸, Natalia Machado¹⁹, Olivio Malheiro²⁰, Rejane Vieira²¹, Ricardo Lage²⁰, Rita Menin²², Rywka Golebiovski²³, Sandra Ribeiro¹², Thauana Oliveira²³, Valquiria Diniz¹⁶, Percival Sampaio-Barros²⁴ and Carla Saad², ¹Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ³Hospital das Clinicas UFMG, Belo Horizonte, Brazil, ⁴UNIFESP/ EPM, São Paulo, São Paulo, Brazil, ⁵Hospital das Clinicas - Universidade Federal de Pernambuco - UFPE, Recife, Pernambuco, Brazil, ⁶Fundação Hospital do Acre - AC, Rio Branco, Brazil, ⁷Hospital Universitário da Universidade Federal de Santa Catarina (UFSC) - SC, Florianópolis, Brazil, ⁸UNB, Brasilia, Distrito Federal, Brazil, ⁹Fundação Hospital do Acre - AC, Rio Branco, Acre, Brazil, ¹⁰Faculdade de Medicina da Universidade Federal do Amazonas (UFAM) - AM, Manaus, Brazil, ¹¹Hospital Governador Celso Ramos (HCR) - SC, Florianópolis, Santa Catarina, Brazil, ¹²Faculdade de Medicina da Universidade Federal do Amazonas (UFAM) - AM, Manaus, Amazonas, Brazil, ¹³Hospital de Base do Distrito Federal (HBDF) - DF, Brasilia, Distrito Federal, Brazil, ¹⁴Universidade Federal do Maranhão (UFMA) - MA, São Luiz, Maranhao, Brazil, ¹⁵Hospital Universitário Pedro Ernesto / UERJ - RJ, Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁶Universidade Federal do Espírito Santo (UFES) - ES, Vitória, Espirito Santo, Brazil, ¹⁷Universidade Estadual de Campinas (UNICAMP) - SP, Campinhas, Sao Paulo, Brazil, ¹⁸Hospital das Clínicas da Universidade Federal de Pernambuco (UFPE) - PE, Recife, Pernambuco, Brazil, ¹⁹Universidade Fedral do Paraná (UFPR) - PR, Curitiba, Parana, Brazil, ²⁰Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG) - MG, Belo Horizonte, Minas Gerais, Brazil, ²¹Universidade Estadual do Ceará (UECE) - CE, Fortaleza, Ceara, Brazil, ²²Faculdade de Medicina de São José do Rio Preto (FAMERP) - SP, São José do Rio Preto, Sao Paulo, Brazil, ²³Escola Paulista de Medicina (EPM) - Universidade Federal de São Paulo (UNIFESP) - SP, São Paulo, Sao Paulo, Brazil, ²⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil
Background/Purpose: Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease that impairs quality of life. While pharmacological treatment is central to axSpA management, non-pharmacological strategies are…
Abstract Number: 1452 • ACR Convergence 2025
Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
Nikolaos Kougkas¹, Konstantinos Tsafis², Dimitrios Deligeorgakis³, Vasileios Papadopoulos⁴, Nikolaos Fytanidis⁵, Michail Krikelis⁶, Evangelia Mole⁷, Sousana Gazi⁷, Nikolaos Koletsos⁸, EVRIPIDIS KALTSONOUDIS⁹, Paraskevi V Voulgari¹⁰, Anastasios Karamanakos¹¹, Maria Pappa¹², Maria Tektonidou¹³, Petros Sfikakis¹⁴, Kalliopi Klavdianou¹⁵, aggelos Banos¹⁶, Eleni Kalavri¹⁷, Konstantinos Kottas¹⁸, Gkikas Katsifis¹⁸, MARIA KONSTA¹⁹, Eleftheria Grika²⁰, Charalampos Sfontouris²⁰, Evgenia Mavrea²¹, Christos Koutsianas²², Evangelia Kataxaki²³, Eleni Sampatakaki²⁴, Konstantina Zoupidou²⁵, Pelagia Katsimpri²⁶, Alexios Iliopoulos²⁷, Georgios Iliopoulos²⁸, Dimitrios Daousis²⁹, Ilias Bournazos³⁰, DIMITRIOS KAROKIS³¹, Dimos Patrikos³², Theodoros Dimitroulas³, Dimitrios Vassilopoulos²¹, George E Fragoulis³³ and Charalampos Papagoras³⁴, ¹⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ²Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Thessaloniki, Greece, ³Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Greece, ⁴Department of Medicine Democritus University of Thrace, Laboratory of Anatomy, Alexandroupolis, Greece, Alexandroupolis, Evros, Greece, ⁵University Hospital of Alexandroupolis, Democritus University of Thrace, First Department of Internal Medicine, Alexandroupolis, Greece, Alexandroupolis, Greece, ⁶KAT Hospital, Athens, Department of Rheumatology, Athens, Greece,, Athens, Attiki, Greece, ⁷Rheumatology department, KAT General Hospital of Attica, Athens, Attiki, Greece, ⁸School of Health Sciences, Faculty of Medicine, University of Ioannina, Department of Rheumatology, Ioannina, Greece, Ioannina, Ioannina, Greece, ⁹Rheumatology Clinic, University of Ioannina, IOANNINA, Ioannina, Greece, ¹⁰Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece, ¹¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Laiko”, First Department of Propedeutic and Internal Medicine, Athens, Greece, Athens, Greece, ¹²Rheumatology and Clinical Immunology Unit, ⁴th Department of Internal Medicine, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ¹³National and Kapodistrian University of Athens, Athens, Greece, ¹⁴NKUA - SCHOOL OF MEDICINE, Athens, Greece, ¹⁵Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Kaisariani Athens, Greece, ¹⁶Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Athens, Attiki, Greece, ¹⁷"Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Athens, Greece, ¹⁸Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, Athens, Greece, ¹⁹Sismanoglion Hospital, Athens, Greece, Marousi, Attiki, Greece, ²⁰Evaggelismos Athens General Hospital, Department of Rheumatology, Athens, Greece, Athens, Greece, ²¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Clinical Immunology-Rheumatology Unit, ²nd Department of Medicine and Laboratory, Athens, Greece, Athens, Greece, ²²Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Athens, Greece, ²³General Hospital Elefsinas Thriaseio,Attica, Rheumatology Department, Athens, Greece, Athens, Greece, ²⁴Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Attiki, Greece, ²⁵Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Greece, ²⁶Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ²⁷⁴¹⁷ Army Share Fund Hospital (NIMTS), Department of Rheumatology, Athens, Greece, ZOGRAFOU, Greece, ²⁸Patras University Hospital, University of Patras Medical School, Department of Rheumatology, Patras, Greece, Patras, Akhaia, Greece, ²⁹Patras University Hospital, University of Patras Medical School, Department of Rheumatology, Patras, Greece, Patra, Greece, ³⁰Private practice, Athens, Greece, Athens, Greece, ³¹Private practice, Patras, Greece, Patras, Greece, ³²Private practice, Athens, Greece, Ag. Paraskevi, Greece, ³³First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ³⁴First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease that significantly impairs quality of life. Although biologic and targeted synthetic DMARDs (b/tsDMARDs) have improved disease…
Abstract Number: 1408 • ACR Convergence 2025
When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden
Claudia Marques¹, Gustavo Resende², Carla Saad³, Adriana Marinho⁴, Andressa Soares⁵, Beatriz Paiva⁶, Cleandro Pires⁷, Débora Rodrigues⁸, Glaucio Castro⁹, Guilherme Bulbol¹⁰, Jamile Carneiro¹¹, Manuella Ochtrop¹², José Mauro Fernandes¹³, Maria Bernadete Gavi¹⁴, Maria Eduarda Veiga³, Michel Yazbek¹⁵, Nara Cavalcanti¹⁶, Natalia Machado¹⁷, Olivio Malheiro¹⁸, Rafael Bassara Macedo¹⁹, Rejane Vieira²⁰, Ricardo Lage¹⁸, Rita Menin²¹, Rywka Golebiovski²², Sandra Ribeiro¹⁰, Thauana Oliveira²², Valquiria Diniz¹⁴, Percival Sampaio-Barros²³ and Marcelo Pinheiro²⁴, ¹Hospital das Clinicas - Universidade Federal de Pernambuco - UFPE, Recife, Pernambuco, Brazil, ²Hospital das Clinicas UFMG, Belo Horizonte, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Fundação Hospital do Acre - AC, Rio Branco, Brazil, ⁵Hospital Universitário da Universidade Federal de Santa Catarina (UFSC) - SC, Florianópolis, Brazil, ⁶Faculdade de Medicina da Universidade Federal do Amazonas (UFAM) - AM, Manaus, Brazil, ⁷UNB, Brasilia, Distrito Federal, Brazil, ⁸Fundação Hospital do Acre - AC, Rio Branco, Acre, Brazil, ⁹Hospital Governador Celso Ramos (HCR) - SC, Florianópolis, Santa Catarina, Brazil, ¹⁰Faculdade de Medicina da Universidade Federal do Amazonas (UFAM) - AM, Manaus, Amazonas, Brazil, ¹¹Hospital de Base do Distrito Federal (HBDF) - DF, Brasilia, Distrito Federal, Brazil, ¹²Hospital Universitário Pedro Ernesto / UERJ - RJ, Rio de Janeiro, Rio de Janeiro, Brazil, ¹³Universidade Federal do Maranhão (UFMA) - MA, São Luiz, Maranhao, Brazil, ¹⁴Universidade Federal do Espírito Santo (UFES) - ES, Vitória, Espirito Santo, Brazil, ¹⁵Universidade Estadual de Campinas (UNICAMP) - SP, Campinhas, Sao Paulo, Brazil, ¹⁶Hospital das Clínicas da Universidade Federal de Pernambuco (UFPE) - PE, Recife, Pernambuco, Brazil, ¹⁷Universidade Fedral do Paraná (UFPR) - PR, Curitiba, Parana, Brazil, ¹⁸Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG) - MG, Belo Horizonte, Minas Gerais, Brazil, ¹⁹Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, ²⁰Universidade Estadual do Ceará (UECE) - CE, Fortaleza, Ceara, Brazil, ²¹Faculdade de Medicina de São José do Rio Preto (FAMERP) - SP, São José do Rio Preto, Sao Paulo, Brazil, ²²Escola Paulista de Medicina (EPM) - Universidade Federal de São Paulo (UNIFESP) - SP, São Paulo, Sao Paulo, Brazil, ²³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ²⁴UNIFESP/ EPM, São Paulo, São Paulo, Brazil
Background/Purpose: Sex differences in axial spondyloarthritis (axSpA) are well recognized, but their clinical consequences remain understudied in real-world settings. This study aimed to assess sex-based…
Abstract Number: 0546 • ACR Convergence 2025
Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study
Paras Karmacharya¹, Dilli Poudel², Daniel Shin³, Robert Fitzsimmons³, Leslie Crofford⁴ and Alexis Ogdie⁵, ¹Vanderbilt University, Nashville, TN, Hermitage, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³University of Pennsylvania, Philadelphia, ⁴Vanderbilt University Medical Center, Melbourne, AR, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Multimorbidity (≥ 2 chronic conditions) is common in inflammatory diseases such as psoriatic arthritis (PsA), psoriasis (PsO), and axial spondyloarthritis (AxSpA), increasing patient burden…
Abstract Number: 2634 • ACR Convergence 2025
Sex differences in medication discontinuation in axial spondyloarthritis
Rachael Stovall¹, Cinthia Blat², Eric Roberts³, Jean Liew⁴, Katherine Wysham⁵, Namrata Singh¹, Janna Friedly¹, Lianne S. Gensler⁶, gabriela Schmajuk⁷ and Jinoos Yazdany⁸, ¹University of Washington, Seattle, WA, ²University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, SF, CA, ⁴Boston University School of Medicine, Boston, MA, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁸UCSF, San Francisco, CA
Background/Purpose: Women with axial spondyloarthritis (axSpA) tend to report worse outcomes and greater functional impairment than men. They may also respond less favorably to medication,…

1
2
3
…
67
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].